Evidence map›Paper›PMID 32475810›Full record

SynthesisLife sciences2020

The role of biomarkers in diagnosis of COVID-19 - A systematic review.

Muhammed Kermali, Raveena Kaur Khalsa, Kiran Pillai, Zahra Ismail, Amer Harky

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 344 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
344citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

344 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

284 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muhammed KermaliSt. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Raveena Kaur KhalsaSt. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Kiran PillaiSt. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Zahra IsmailSt. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Amer HarkyDepartment of Cardio-thoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK. Electronic address: aaharky@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsAs of the 28th April 2020, the COVID-19 pandemic has infiltrated over 200 countries and affected over three million confirmed people. We review different biomarkers to evaluate if they are able to predict clinical outcomes and correlate with the severity of COVID-19 disease.

methodsA systematic review of the literature was carried out to identify relevant articles using six different databases. Keywords to refine the search included 'COVID-19', 'SARS-CoV2', 'Biomarkers', among others. Only studies which reported data on pre-defined outcomes were included. KEY

findingsThirty-four relevant articles were identified which reviewed the following biomarkers: C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, renal biomarkers, lymphocytes and platelet count. Of these, all but two, showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts. Lymphocytes and platelet count showed significantly lower levels in severe patients compared to non-severe patients. SIGNIFICANCE: Although research is still in its early stages, the discovery of how different biomarkers behave during the course of the disease could help clinicians in identifying severe disease earlier and subsequently improve prognosis. Nevertheless, we urge for more research across the globe to corroborate these findings.

Indexed as

BetacoronavirusBiomarkersClinical Laboratory TechniquesCoronavirus InfectionsCOVID-19COVID-19 TestingC-Reactive ProteinFibrin Fibrinogen Degradation ProductsHumansInterleukin-6KidneyL-Lactate DehydrogenaseLymphocyte CountNeutrophilsPandemicsPlatelet CountBiomarkersC-Reactive ProteinFibrin Fibrinogen Degradation Productsfibrin fragment DIL6 protein, humanInterleukin-6L-Lactate DehydrogenaseSerum Amyloid A ProteinTroponin IBiomarkersBlood testsCOVID-19SARS-CoV-2

Identifiers

PMID32475810
PMCPMC7219356

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.